Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy

There is increasing evidence that hypertension may contribute to development of dementia. Studies show that blood pressure lowering therapy might protect against cognitive deterioration and that antihypertensive treatment reduce the incidence of dementia.

[1]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[2]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[3]  T. Hemnani,et al.  Alzheimer’s disease pathogenesis and therapeutic interventions , 2004, Journal of Clinical Neuroscience.

[4]  H. Arai,et al.  Angiotensin‐Converting Enzyme Inhibitors and Incidence of Alzheimer's Disease in Japan , 2004, Journal of the American Geriatrics Society.

[5]  A. Routtenberg,et al.  Angiotensin injected into the neostriatum after learning disrupts retention performance. , 1977, Science.

[6]  J. O'Brien,et al.  Drugs for Alzheimer's disease , 2001, BMJ : British Medical Journal.

[7]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[8]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[9]  J. Noble,et al.  Drugs for Alzheimer's disease , 2001, BMJ : British Medical Journal.

[10]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[11]  Second Edition,et al.  Statistical Package for the Social Sciences , 1970 .

[12]  J. Staessen,et al.  Dementia and antihypertensive treatment. , 2004, Current opinion in nephrology and hypertension.

[13]  S. Katz,et al.  Progress in development of the index of ADL. , 1970, The Gerontologist.

[14]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[15]  P. Tariot,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.

[16]  V. Kostic,et al.  Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. , 1997, The International journal of neuroscience.

[17]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[18]  B. Costall,et al.  Angiofensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease , 1991 .

[19]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[20]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[21]  T. Erkinjuntti,et al.  POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINS , 2003, International journal of clinical practice.

[22]  R. Anand,et al.  An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors , 2000, European journal of neurology.

[23]  C. Bulpitt,et al.  Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial , 2004, Journal of hypertension.

[24]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[25]  M. Farlow,et al.  A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.

[26]  C. Hock,et al.  Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia , 2001, Neurobiology of Aging.

[27]  F. Graeff,et al.  Effect of intracerebroventricular bradykinin and related peptides on rabbit operant behavior. , 1975, Journal of Pharmacology and Experimental Therapeutics.

[28]  T. Crook,et al.  Angiotensin converting enzyme and memory: preclinical and clinical data. , 1987, International journal of neurology.

[29]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[30]  P. Ghisdal,et al.  Intraneuronal amyloid‐β1‐42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death , 2004, Journal of neurochemistry.

[31]  N. Hirawa,et al.  Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. , 1999, Hypertension.

[32]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.